| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2024―Mar―13 |
Author Correction: Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation |
Laure F. Pittet, Christie C. A. Noble, Nicole L. Messina, Nigel Curtis |
| 2 |
[GO] |
2024―Jan―18 |
Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation |
Laure F. Pittet, Christie C. A. Noble, Nicole L. Messina, Nigel Curtis |
| 3 |
[GO] |
2023―Nov―08 |
Gut fungi have lasting effect on immune response to severe COVID-19 |
Alexandra Flemming |
| 4 |
[GO] |
2023―Nov―07 |
Low serotonin linked to long COVID |
Lucy Bird |
| 5 |
[GO] |
2023―Oct―10 |
The distinctive immune features of long COVID |
Alexandra Flemming |
| 6 |
[GO] |
2023―Oct―06 |
Tracking the infant immune response to SARS-CoV-2 |
Yvonne Bordon |
| 7 |
[GO] |
2023―Sep―18 |
Author Correction: The immunology of long COVID |
Daniel M. Altmann, Emily M. Whettlock, Siyi Liu, Deepa J. Arachchillage, Rosemary J. Boyton |
| 8 |
[GO] |
2023―Sep―15 |
Lung-migrating helminths can enhance immunity to SARS-CoV-2 |
Yvonne Bordon |
| 9 |
[GO] |
2023―Jul―25 |
Asymptomatic SARS-CoV-2 linked to HLA-B*15:01 |
Yvonne Bordon |
| 10 |
[GO] |
2023―Jul―11 |
The immunology of long COVID |
Daniel M. Altmann, Emily M. Whettlock, Siyi Liu, Deepa J. Arachchillage, Rosemary J. Boyton |
| 11 |
[GO] |
2023―Mar―14 |
Autoantibodies against chemokines linked with better disease outcomes in COVID-19 |
Yvonne Bordon |
| 12 |
[GO] |
2023―Mar―14 |
Repurposing metabolic drugs for COVID-19 |
Yvonne Bordon |
| 13 |
[GO] |
2022―Dec―20 |
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses |
Sam M. Murray, Azim M. Ansari, John Frater, Paul Klenerman, Susanna Dunachie, Eleanor Barnes, Ane Ogbe |
| 14 |
[GO] |
2022―Dec―20 |
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines |
Yi Ju, Juan Manuel Carreño, Viviana Simon, Kenneth Dawson, Florian Krammer, Stephen J. Kent |
| 15 |
[GO] |
2022―Dec―19 |
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection |
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, Yona Tugg, Art Marzok, Matthew S. Miller |
| 16 |
[GO] |
2022―Dec―09 |
Unique properties of tissue-resident memory T cells in the lungs: implications for COVID-19 and other respiratory diseases |
Francis R. Carbone |
| 17 |
[GO] |
2022―Nov―08 |
‘Prime and spike’ induces mucosal immunity and reduces SARS-CoV-2 transmission |
Alexandra Flemming |
| 18 |
[GO] |
2022―Oct―05 |
COVID-19 and cellular senescence |
Clemens A. Schmitt, Tamar Tchkonia, Laura J. Niedernhofer, Paul D. Robbins, James L. Kirkland, Soyoung Lee |
| 19 |
[GO] |
2022―Sep―27 |
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses |
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, Huanzhang Zhu, Shibo Jiang, Pengfei Wang |
| 20 |
[GO] |
2022―Aug―09 |
SARS-CoV-2 hybrid immunity: silver bullet or silver lining? |
Rahul Suryawanshi, Melanie Ott |
| 21 |
[GO] |
2022―Aug―05 |
Understanding COVID-19-associated coagulopathy |
Edward M. Conway, Nigel Mackman, Ronald Q. Warren, Alisa S. Wolberg, Laurent O. Mosnier, Robert A. Campbell, et al. (+8) Lisa E. Gralinski, Matthew T. Rondina, Frank L. van de Veerdonk, Karin M. Hoffmeister, John H. Griffin, Diane Nugent, Kyung Moon, James H. Morrissey |
| 22 |
[GO] |
2022―Jul―22 |
Vitamin D for COVID-19: where are we now? |
Adrian R. Martineau, Margherita T. Cantorna |
| 23 |
[GO] |
2022―Jul―13 |
Respiratory syncytial virus after the SARS-CoV-2 pandemic - what next? |
Lucy G. Mosscrop, Thomas C. Williams, John S. Tregoning |
| 24 |
[GO] |
2022―Jul―04 |
Considering innate immune responses in SARS-CoV-2 infection and COVID-19 |
Michael S. Diamond, John D. Lambris, Jenny P. Ting, John S. Tsang |
| 25 |
[GO] |
2022―Jun―29 |
When ‘mild’ COVID-19 is not so mild |
Kirsty Minton |
| 26 |
[GO] |
2022―Jun―29 |
Mechanistic insights into Long COVID in hamsters |
Kirsty Minton |
| 27 |
[GO] |
2022―Jun―10 |
Diabetes enhances viral loads in COVID-19 |
Alexandra Flemming |
| 28 |
[GO] |
2022―Jun―10 |
Vaccines only partially protect against Long COVID |
Alexandra Flemming |
| 29 |
[GO] |
2022―Jun―07 |
COVID-19 and Down syndrome: the spark in the fuel |
Manini Majithia, Susan P. Ribeiro |
| 30 |
[GO] |
2022―May―24 |
Cardiometabolic syndrome - an emergent feature of Long COVID? |
Justin J. Frere, Benjamin R. tenOever |
| 31 |
[GO] |
2022―Apr―28 |
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? |
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, Jennifer A. Juno, Adam K. Wheatley, Eva Stadler, et al. (+5) E. John Wherry, James Triccas, Sarah C. Sasson, Deborah Cromer, Miles P. Davenport |
| 32 |
[GO] |
2022―Apr―19 |
SARS-CoV-2: from herd immunity to hybrid immunity |
David Goldblatt |
| 33 |
[GO] |
2022―Apr―12 |
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections |
Alex Sigal, Ron Milo, Waasila Jassat |
| 34 |
[GO] |
2022―Apr―08 |
Do individuals who have recovered from COVID-19 still benefit from being vaccinated? |
Alexandra Flemming |
| 35 |
[GO] |
2022―Mar―31 |
ORF9c and ORF10 as accessory proteins of SARS-CoV-2 in immune evasion |
Milad Zandi |
| 36 |
[GO] |
2022―Mar―28 |
Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19 |
Pietro Enea Lazzerini, Franco Laghi-Pasini, Mohamed Boutjdir, Pier Leopoldo Capecchi |
| 37 |
[GO] |
2022―Mar―18 |
SARS-CoV-2 infection and COVID-19 vaccination in pregnancy |
Victoria Male |
| 38 |
[GO] |
2022―Mar―14 |
A new set of genes linked to critical COVID-19 |
Yvonne Bordon |
| 39 |
[GO] |
2022―Mar―14 |
Comparing paediatric COVID-19 with MIS-C |
Yvonne Bordon |
| 40 |
[GO] |
2022―Mar―14 |
Social distancing plus rapid vaccination prevents emergence of SARS-CoV-2 variants |
Yvonne Bordon |
| 41 |
[GO] |
2022―Feb―15 |
First glimpses into the mechanisms of Long COVID |
Alexandra Flemming |
| 42 |
[GO] |
2022―Feb―15 |
Lessons from Long COVID: working with patients to design better research |
Nisreen A. Alwan |
| 43 |
[GO] |
2022―Feb―10 |
Modelling vaccination strategies for COVID-19 |
Caroline E. Wagner, Chadi M. Saad-Roy, Bryan T. Grenfell |
| 44 |
[GO] |
2021―Dec―17 |
Author Correction: Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? |
Lok-Yin Roy Wong, Stanley Perlman |
| 45 |
[GO] |
2021―Dec―15 |
The state of complement in COVID-19 |
Behdad Afzali, Marina Noris, Bart N. Lambrecht, Claudia Kemper |
| 46 |
[GO] |
2021―Dec―13 |
Author Correction: SARS-CoV-2 and HIV-1 - A Tale of Two Vaccines |
Barton F. Haynes |
| 47 |
[GO] |
2021―Dec―07 |
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact |
Marc Lipsitch, Florian Krammer, Gili Regev-Yochay, Yaniv Lustig, Ran D. Balicer |
| 48 |
[GO] |
2021―Dec―06 |
The germinal centre B cell response to SARS-CoV-2 |
Brian J. Laidlaw, Ali H. Ellebedy |
| 49 |
[GO] |
2021―Dec―06 |
Cross-reactive memory T cells abort SARS-CoV-2 infection |
Alexandra Flemming |
| 50 |
[GO] |
2021―Dec―03 |
Dexamethasone restrains neutrophils in severe COVID-19 |
Alexandra Flemming |
| 51 |
[GO] |
2021―Dec―03 |
Defective viral genomes can protect against SARS-CoV-2 variants and other respiratory viruses |
Alexandra Flemming |
| 52 |
[GO] |
2021―Nov―26 |
Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? |
Lok-Yin Roy Wong, Stanley Perlman |
| 53 |
[GO] |
2021―Nov―05 |
Comparing neurological complications after COVID-19 vaccination and SARS-CoV-2 infection |
Alexandra Flemming |
| 54 |
[GO] |
2021―Nov―05 |
Foetal sex affects maternal and placental immune responses to SARS-CoV-2 |
Alexandra Flemming |
| 55 |
[GO] |
2021―Nov―05 |
SARS-CoV-2 Delta variant excels at membrane fusion, but not immune evasion |
Alexandra Flemming |
| 56 |
[GO] |
2021―Oct―19 |
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? |
Rosemary J. Boyton, Daniel M. Altmann |
| 57 |
[GO] |
2021―Oct―05 |
Cross-reactive tissue-resident CD8+ T cells may provide first line of defence against SARS-CoV-2 |
Alexandra Flemming |
| 58 |
[GO] |
2021―Sep―14 |
Negative impact of the COVID-19 pandemic on routine childhood immunization: experience from Pakistan |
Muhammad Suleman Rana, Aamer Ikram, Muhammad Salman, Muhammad Usman, Massab Umair |
| 59 |
[GO] |
2021―Sep―08 |
T cell-oriented strategies for controlling the COVID-19 pandemic |
Ji Yun Noh, Hye Won Jeong, Jerome H. Kim, Eui-Cheol Shin |
| 60 |
[GO] |
2021―Aug―10 |
Poor nasal immunity can lead to severe COVID-19 |
Alexandra Flemming |
| 61 |
[GO] |
2021―Aug―10 |
Detecting future coronavirus pandemics |
Alexandra Flemming |
| 62 |
[GO] |
2021―Aug―09 |
Inflammasome activation at the crux of severe COVID-19 |
Setu M. Vora, Judy Lieberman, Hao Wu |
| 63 |
[GO] |
2021―Aug―09 |
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape |
John S. Tregoning, Katie E. Flight, Sophie L. Higham, Ziyin Wang, Benjamin F. Pierce |
| 64 |
[GO] |
2021―Aug―04 |
Publisher Correction: SARS-CoV-2 and HIV-1 - a tale of two vaccines |
Barton F. Haynes |
| 65 |
[GO] |
2021―Jul―16 |
SARS-CoV-2 and HIV-1 - a tale of two vaccines |
Barton F. Haynes |
| 66 |
[GO] |
2021―Jul―01 |
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans |
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann |
| 67 |
[GO] |
2021―Jun―24 |
Understanding COVID-19 in Africa |
Sofonias K. Tessema, John N. Nkengasong |
| 68 |
[GO] |
2021―May―14 |
Single-cell atlases dissect tissue destruction by SARS-CoV-2 |
Alexandra Flemming |
| 69 |
[GO] |
2021―May―10 |
Author Correction: Will SARS-CoV-2 variants of concern affect the promise of vaccines? |
Ravindra K. Gupta |
| 70 |
[GO] |
2021―Apr―29 |
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection |
Deborah Cromer, Jennifer A. Juno, David Khoury, Arnold Reynaldi, Adam K. Wheatley, Stephen J. Kent, Miles P. Davenport |
| 71 |
[GO] |
2021―Apr―29 |
Will SARS-CoV-2 variants of concern affect the promise of vaccines? |
Ravindra K. Gupta |
| 72 |
[GO] |
2021―Apr―19 |
Neutralizing monoclonal antibodies for treatment of COVID-19 |
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert L. Gottlieb |
| 73 |
[GO] |
2021―Apr―14 |
Seeing SARS-CoV-2 variants through the eyes of T cells |
Aljawharah Alrubayyi, Dimitra Peppa |
| 74 |
[GO] |
2021―Apr―13 |
Is IL-6 a key cytokine target for therapy in COVID-19? |
Simon A. Jones, Christopher A. Hunter |
| 75 |
[GO] |
2021―Apr―06 |
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 |
Aldo Bonaventura, Alessandra Vecchié, Lorenzo Dagna, Kimberly Martinod, Dave L. Dixon, Benjamin W. Van Tassell, et al. (+5) Francesco Dentali, Fabrizio Montecucco, Steffen Massberg, Marcel Levi, Antonio Abbate |
| 76 |
[GO] |
2021―Apr―01 |
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination |
Sarah Cobey, Daniel B. Larremore, Yonatan H. Grad, Marc Lipsitch |
| 77 |
[GO] |
2021―Mar―15 |
The first 12 months of COVID-19: a timeline of immunological insights |
Thiago Carvalho, Florian Krammer, Akiko Iwasaki |
| 78 |
[GO] |
2021―Mar―12 |
Author Correction: Are COVID-19 vaccines safe in pregnancy? |
Victoria Male |
| 79 |
[GO] |
2021―Mar―05 |
COVID-19 vaccines: modes of immune activation and future challenges |
John R. Teijaro, Donna L. Farber |
| 80 |
[GO] |
2021―Mar―03 |
Are COVID-19 vaccines safe in pregnancy? |
Victoria Male |
| 81 |
[GO] |
2021―Feb―23 |
SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship |
Chrysanthi Skevaki, Antonina Karsonova, Alexander Karaulov, Daria Fomina, Min Xie, Sharon Chinthrajah, et al. (+2) Kari C. Nadeau, Harald Renz |
| 82 |
[GO] |
2021―Feb―20 |
Author Correction: Do rogue antibodies make the difference between mild versus severe COVID-19? |
Alexandra Flemming |
| 83 |
[GO] |
2021―Feb―09 |
Targeting autoantibodies in COVID-19 |
Isabela Pedroza-Pacheco, Persephone Borrow |
| 84 |
[GO] |
2021―Feb―04 |
Do rogue antibodies make the difference between mild versus severe COVID-19? |
Alexandra Flemming |
| 85 |
[GO] |
2021―Feb―04 |
Intracranial inflammatory mediators involved in SARS-CoV-2 neurological manifestations? |
Alexandra Flemming |
| 86 |
[GO] |
2021―Feb―04 |
SARS-CoV-2 variant evades antibodies whilst maintaining fitness |
Alexandra Flemming |
| 87 |
[GO] |
2021―Jan―13 |
What have we learnt so far from COVID-19? |
Peter C. Doherty |
| 88 |
[GO] |
2021―Jan―11 |
Immune readouts from the Oxford COVID-19 vaccine |
Yvonne Bordon |
| 89 |
[GO] |
2021―Jan―11 |
Super(antigen) target for SARS-CoV-2 |
Matthew Brown, Nina Bhardwaj |
| 90 |
[GO] |
2021―Jan―05 |
Endemic SARS-CoV-2 will maintain post-pandemic immunity |
Marc Veldhoen, J. Pedro Simas |
| 91 |
[GO] |
2020―Dec―18 |
Viral targets for vaccines against COVID-19 |
Lianpan Dai, George F. Gao |
| 92 |
[GO] |
2020―Dec―01 |
Mapping host restriction of SARS-CoV-2 |
Ester Gea-Mallorquí |
| 93 |
[GO] |
2020―Dec―01 |
B cell persistence and evolution to SARS-CoV-2 |
Aljawharah Alrubayyi |
| 94 |
[GO] |
2020―Dec―01 |
Cross-viral protection against SARS-CoV-2? |
Sophie G. Reed |
| 95 |
[GO] |
2020―Nov―19 |
Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19 |
Ronen Alon, Mike Sportiello, Stav Kozlovski, Ashwin Kumar, Emma C. Reilly, Alexander Zarbock, et al. (+2) Natalio Garbi, David J. Topham |
| 96 |
[GO] |
2020―Nov―02 |
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models |
David S. Khoury, Adam K. Wheatley, Mitchell D. Ramuta, Arnold Reynaldi, Deborah Cromer, Kanta Subbarao, et al. (+3) David H. O’Connor, Stephen J. Kent, Miles P. Davenport |
| 97 |
[GO] |
2020―Oct―21 |
Immunological considerations for SARS-CoV-2 human challenge studies |
Alexander D. Douglas, Adrian V. S. Hill |
| 98 |
[GO] |
2020―Oct―13 |
At the heart of COVID-19 |
Felix Clemens Richter |
| 99 |
[GO] |
2020―Oct―13 |
IL-18-dependent MAIT cell activation in COVID-19 |
Ester Gea-Mallorquí |
| 100 |
[GO] |
2020―Oct―13 |
Intestinal attenuation of COVID-19 inflammation |
Aljawharah Alrubayyi |
| 101 |
[GO] |
2020―Oct―06 |
Do cross-reactive antibodies cause neuropathology in COVID-19? |
Jakob Kreye, S. Momsen Reincke, Harald Prüss |
| 102 |
[GO] |
2020―Oct―06 |
Cross-reactive memory T cells and herd immunity to SARS-CoV-2 |
Marc Lipsitch, Yonatan H. Grad, Alessandro Sette, Shane Crotty |
| 103 |
[GO] |
2020―Oct―02 |
Fatty monocytes in COVID-19 |
Matthew D. Park |
| 104 |
[GO] |
2020―Oct―02 |
SARS-CoV-2 antibody seroconversion in care home |
Joan Shang, Alvaro Moreira |
| 105 |
[GO] |
2020―Sep―28 |
Keeping track of the SARS-CoV-2 vaccine pipeline |
Edward P. K. Parker, Madhumita Shrotri, Beate Kampmann |
| 106 |
[GO] |
2020―Sep―10 |
COVID-19 herd immunity: where are we? |
Arnaud Fontanet, Simon Cauchemez |
| 107 |
[GO] |
2020―Sep―10 |
The global response to the COVID-19 pandemic: how have immunology societies contributed? |
Faith Osier, Jenny P. Y. Ting, John Fraser, Bart N. Lambrecht, Marta Romano, Ricardo T. Gazzinelli, et al. (+23) Karina R. Bortoluci, Dario S. Zamboni, Arne N. Akbar, Jennie Evans, Doug E. Brown, Kamala D. Patel, Yuzhang Wu, Ana B. Perez, Oliver Pérez, Thomas Kamradt, Christine Falk, Mira Barda-Saad, Amiram Ariel, Angela Santoni, Francesco Annunziato, Marco A. Cassatella, Hiroshi Kiyono, Valeriy Chereshnev, Alioune Dieye, Moustapha Mbow, Babacar Mbengue, Maguette D. S. Niang, Melinda Suchard |
| 108 |
[GO] |
2020―Sep―07 |
Coordinated and sustained immune memory responses after mild COVID-19 |
Aljawharah Alrubayyi |
| 109 |
[GO] |
2020―Sep―07 |
SARS-CoV-2 ORF9c: a mysterious membrane-anchored protein that regulates immune evasion? |
Fangfang Lu |
| 110 |
[GO] |
2020―Sep―07 |
Does a host restriction factor facilitate entry of SARS-CoV-2? |
Ester Gea-Mallorquí |
| 111 |
[GO] |
2020―Sep―04 |
Immunological considerations for COVID-19 vaccine strategies |
Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, Matthew S. Miller, Brian D. Lichty, Zhou Xing |
| 112 |
[GO] |
2020―Sep―01 |
Inhaled nanobodies against COVID-19 |
Gustavo Martinez-Delgado |
| 113 |
[GO] |
2020―Sep―01 |
Immune correlates of SARS-CoV-2 protection |
Matthew Brown |
| 114 |
[GO] |
2020―Sep―01 |
Long-lasting SARS-CoV-2-specific T cell memories |
Cansu Cimen Bozkus |
| 115 |
[GO] |
2020―Aug―24 |
Not just antibodies: B cells and T cells mediate immunity to COVID-19 |
Rebecca J. Cox, Karl A. Brokstad |
| 116 |
[GO] |
2020―Aug―21 |
Altered immune cell differentiation in the lungs of patients with critical COVID-19 |
Erinke van Grinsven, Kathrin Jansen |
| 117 |
[GO] |
2020―Aug―21 |
CD8+ T cells remember same bits of SARS-CoV-2 |
Julie M. Mazet, Ester Gea-Mallorquí |
| 118 |
[GO] |
2020―Aug―21 |
Attacking the defence: SARS-CoV-2 can infect immune cells |
Mariana Borsa, Julie M. Mazet |
| 119 |
[GO] |
2020―Aug―17 |
A cocktail of antibodies for COVID-19 therapy |
Dean B. Matthews |
| 120 |
[GO] |
2020―Aug―17 |
Shared CD8+ T cell receptors for SARS-CoV-2 |
Rachel Levantovsky, Verena van der Heide |
| 121 |
[GO] |
2020―Aug―17 |
Spatial resolution of SARS-CoV-2 lung infection |
Luisanna Pia |
| 122 |
[GO] |
2020―Aug―17 |
Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns |
Alessandro Sette, Shane Crotty |
| 123 |
[GO] |
2020―Aug―12 |
The type I interferon response in COVID-19: implications for treatment |
Jeong Seok Lee, Eui-Cheol Shin |
| 124 |
[GO] |
2020―Aug―11 |
Getting to the (germinal) centre of SARS-CoV-2 |
Felix Clemens Richter, Mariana Borsa |
| 125 |
[GO] |
2020―Aug―11 |
Antibody response to SARS-CoV-2 - sustained after all? |
Ewoud B. Compeer, Lion F. K. Uhl |
| 126 |
[GO] |
2020―Aug―11 |
SARS-CoV-2 vaccine - think globally, act locally |
Ester Gea-Mallorquí, Ewoud B. Compeer |
| 127 |
[GO] |
2020―Aug―10 |
After 62 years of regulating immunity, dexamethasone meets COVID-19 |
Derek W. Cain, John A. Cidlowski |
| 128 |
[GO] |
2020―Aug―10 |
Author Correction: Tissue damage from neutrophil-induced oxidative stress in COVID-19 |
Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, et al. (+2) Jean- Jacques Benoliel, Chrystel Becker |
| 129 |
[GO] |
2020―Aug―04 |
Publisher Correction: NK cells in COVID-19: protectors or opponents? |
Aljawharah Alrubayyi |
| 130 |
[GO] |
2020―Jul―31 |
IgGs drive COVID-19 myeloid hyperinflammation |
Matthew D. Park |
| 131 |
[GO] |
2020―Jul―30 |
NK cells in COVID-19: protectors or opponents? |
Aljawharah Alrubayyi |
| 132 |
[GO] |
2020―Jul―29 |
Tissue damage from neutrophil-induced oxidative stress in COVID-19 |
Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, et al. (+2) Jean-Jacques Benoliel, Chrystel Becker |
| 133 |
[GO] |
2020―Jul―29 |
T cell responses in patients with COVID-19 |
Zeyu Chen, E. John Wherry |
| 134 |
[GO] |
2020―Jul―20 |
Virus dissociated from inflammation in fatal COVID-19 |
Meriem Belabed |
| 135 |
[GO] |
2020―Jul―20 |
Antibody responses to SARS-CoV-2 short-lived |
Nicolas Vabret |
| 136 |
[GO] |
2020―Jul―10 |
T cell renaissance in COVID-19 |
Lee Garner, Liliana Cifuentes |
| 137 |
[GO] |
2020―Jul―10 |
CRISPRing for host genes regulating SARS-CoV-2 |
Fangfang Lu, Michael Tellier |
| 138 |
[GO] |
2020―Jul―10 |
SARS-CoV-2 on the neural battleground |
Clara Eléonore Pavillet, Tharini Ashtalakshmi Selvakumar |
| 139 |
[GO] |
2020―Jul―07 |
COVID-19 and influenza: preparing for the storm |
Matthew D. Park |
| 140 |
[GO] |
2020―Jul―07 |
SARS-CoV-2-specific T cells without antibodies |
Cansu Cimen Bozkus |
| 141 |
[GO] |
2020―Jul―07 |
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns |
Alessandro Sette, Shane Crotty |
| 142 |
[GO] |
2020―Jul―02 |
A call to arms: helping family, friends and communities navigate the COVID-19 infodemic |
Heidi J. Larson |
| 143 |
[GO] |
2020―Jun―26 |
SARS-CoV-2: too infectious to handle? |
Clarissa Coveney, Jennifer Alderson |
| 144 |
[GO] |
2020―Jun―23 |
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches |
Frederick M. Lang, Kevin M.-C. Lee, John R. Teijaro, Burkhard Becher, John A. Hamilton |
| 145 |
[GO] |
2020―Jun―22 |
Sex differences in immune responses in COVID-19 |
Matthew D. Park |
| 146 |
[GO] |
2020―Jun―22 |
Roles for eosinophils and basophils in COVID-19? |
Alexandra Tabachnikova, Steven T. Chen |
| 147 |
[GO] |
2020―Jun―22 |
Preclinical data from SARS-CoV-2 mRNA vaccine |
Nicolas Vabret |
| 148 |
[GO] |
2020―Jun―18 |
Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? |
Shen-Ying Zhang, Qian Zhang, Jean-Laurent Casanova, Helen C. Su |
| 149 |
[GO] |
2020―Jun―17 |
Optimizing safety surveillance for COVID-19 vaccines |
Rebecca E. Chandler |
| 150 |
[GO] |
2020―Jun―16 |
Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children |
Anne H. Rowley |
| 151 |
[GO] |
2020―Jun―12 |
A versatile mouse model of COVID-19 |
Helene Borrmann, Rachel E. Rigby |
| 152 |
[GO] |
2020―Jun―12 |
Publisher Correction: Risk factors for death from COVID-19 |
Myvizhi Esai Selvan |
| 153 |
[GO] |
2020―Jun―12 |
Passive antibody therapy in COVID-19 |
Jonathan Abraham |
| 154 |
[GO] |
2020―Jun―12 |
Author Correction: Complement as a target in COVID-19? |
Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris |
| 155 |
[GO] |
2020―Jun―12 |
SARS-CoV-2 has a sweet tooth |
Athena Cavounidis, Elizabeth H. Mann |
| 156 |
[GO] |
2020―Jun―11 |
Considering how biological sex impacts immune responses and COVID-19 outcomes |
Eileen P. Scully, Jenna Haverfield, Rebecca L. Ursin, Cara Tannenbaum, Sabra L. Klein |
| 157 |
[GO] |
2020―Jun―08 |
Dissecting antibody-mediated protection against SARS-CoV-2 |
Tomer Zohar, Galit Alter |
| 158 |
[GO] |
2020―Jun―05 |
Many paths to COVID-19 lymphocyte dysfunction |
Samarth Hegde |
| 159 |
[GO] |
2020―Jun―05 |
SARS-CoV-2 cross-reactivity in healthy donors |
Verena van der Heide |
| 160 |
[GO] |
2020―Jun―05 |
Immune evasion via SARS-CoV-2 ORF8 protein? |
Matthew D. Park |
| 161 |
[GO] |
2020―Jun―04 |
COVID-19 vaccines: neutralizing antibodies and the alum advantage |
Peter J. Hotez, David B. Corry, Ulrich Strych, Maria Elena Bottazzi |
| 162 |
[GO] |
2020―Jun―04 |
Author Correction: COVID-19: the vasculature unleashed |
Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet |
| 163 |
[GO] |
2020―Jun―02 |
Blood clots and TAM receptor signalling in COVID-19 pathogenesis |
Greg Lemke, Gregg J. Silverman |
| 164 |
[GO] |
2020―Jun―02 |
Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
Miriam Merad, Jerome C. Martin |
| 165 |
[GO] |
2020―May―27 |
Risk factors for death from COVID-19 |
Myvizhi Esai Selvan |
| 166 |
[GO] |
2020―May―27 |
Kawasaki disease linked to COVID-19 in children |
Alvaro Moreira |
| 167 |
[GO] |
2020―May―27 |
Innate T cells in COVID-19: friend or foe? |
Verena van der Heide |
| 168 |
[GO] |
2020―May―26 |
Dysregulation of type I interferon responses in COVID-19 |
Dhiraj Acharya, GuanQun Liu, Michaela U. Gack |
| 169 |
[GO] |
2020―May―21 |
COVID-19: the vasculature unleashed |
Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet |
| 170 |
[GO] |
2020―May―14 |
Modulation of immune crosstalk in COVID-19 |
Bérengère Salomé, Zafar Mahmood |
| 171 |
[GO] |
2020―May―14 |
SARS-CoV-2 likes it cool |
Alessandra Soares-Schanoski |
| 172 |
[GO] |
2020―May―11 |
BCG-induced trained immunity: can it offer protection against COVID-19? |
Luke A. J. O’Neill, Mihai G. Netea |
| 173 |
[GO] |
2020―May―06 |
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
Miriam Merad, Jerome C. Martin |
| 174 |
[GO] |
2020―May―01 |
Will helminth co-infection modulate COVID-19 severity in endemic regions? |
Richard S. Bradbury, David Piedrafita, Andrew Greenhill, Siddhartha Mahanty |
| 175 |
[GO] |
2020―May―01 |
COVID-19: a case for inhibiting IL-17? |
Omar Pacha, Mary Alice Sallman, Scott E. Evans |
| 176 |
[GO] |
2020―Apr―30 |
Impaired interferon signature in severe COVID-19 |
Conor Gruber |
| 177 |
[GO] |
2020―Apr―30 |
Inactivated vaccine for SARS-CoV-2 |
Emma Risson |
| 178 |
[GO] |
2020―Apr―30 |
SARS-CoV-2-reactive T cells in patients and healthy donors |
Luisanna Pia |
| 179 |
[GO] |
2020―Apr―28 |
Neutralizing antibody response in mild COVID-19 |
Verena van der Heide |
| 180 |
[GO] |
2020―Apr―28 |
COVID-19 vaccine design: the Janus face of immune enhancement |
Peter J. Hotez, David B. Corry, Maria Elena Bottazzi |
| 181 |
[GO] |
2020―Apr―28 |
Cancer therapy tool informs COVID-19 vaccines |
Miriam Saffern |
| 182 |
[GO] |
2020―Apr―28 |
Does asthma make COVID-19 worse? |
Samarth Hegde |
| 183 |
[GO] |
2020―Apr―28 |
The trinity of COVID-19: immunity, inflammation and intervention |
Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, Paul A. MacAry, Lisa F. P. Ng |
| 184 |
[GO] |
2020―Apr―23 |
Complement as a target in COVID-19? |
Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris |
| 185 |
[GO] |
2020―Apr―23 |
Advancing scientific knowledge in times of pandemics |
Nicolas Vabret, Robert Samstein, Nicolas Fernandez, Miriam Merad |
| 186 |
[GO] |
2020―Apr―21 |
The potential danger of suboptimal antibody responses in COVID-19 |
Akiko Iwasaki, Yexin Yang |
| 187 |
[GO] |
2020―Apr―17 |
Macrophages: a Trojan horse in COVID-19? |
Matthew D. Park |
| 188 |
[GO] |
2020―Apr―17 |
Will we see protection or reinfection in COVID-19? |
Miyo Ota |
| 189 |
[GO] |
2020―Apr―17 |
A map of SARS-CoV-2 and host cell interactions |
Louise Malle |
| 190 |
[GO] |
2020―Apr―15 |
COVID-19: risk for cytokine targeting in chronic inflammatory diseases? |
Georg Schett, Michael Sticherling, Markus F. Neurath |
| 191 |
[GO] |
2020―Apr―14 |
Coronaviruses hijack the complement system |
C. Matthias Wilk |
| 192 |
[GO] |
2020―Apr―14 |
Human antibodies can neutralize SARS-CoV-2 |
Jovani Catalan-Dibene |
| 193 |
[GO] |
2020―Apr―09 |
COVID-19: immunopathology and its implications for therapy |
Xuetao Cao |
| 194 |
[GO] |
2020―Apr―06 |
Dysregulation of lung myeloid cells in COVID-19 |
Bérengère Salomé, Assaf Magen |
| 195 |
[GO] |
2020―Apr―06 |
In the eye of the COVID-19 cytokine storm |
Natalie Vaninov |
| 196 |
[GO] |
2020―Apr―06 |
Fighting COVID-19 exhausts T cells |
Chang Moon |
